$ 8.02
Key Takeaways
Risk factor
Low price volatility
Profitability factor
Greatly undervalued vs peers
About
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD
Target Price
The average target price of BAYRY is 9.9 and suggests 24% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
